Mismatch Repair Deficiency in Patients with Double Primary Cancer of the Colorectum and Stomach by Takemoto, Hiroki & Makino, Masato
117
Yonago Acta medica 2003;46:117–124
Abbreviations:  CRC, colorectal cancer; HNPCC, hereditary nonpolyposis colorectal cancer; MMR, mismatch repair;
MSI, microsatellite instability
Mismatch Repair Deficiency in Patients with Double Pri-
mary Cancer of the Colorectum and Stomach
Hiroki Takemoto and Masato Makino
Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University
Faculty of Medicine, Yonago 683-8504 Japan
We examined the correlation between the expression of mismatch repair (MMR) gene
proteins and the development of double primary cancer, and studied clinical implications
of an MMR deficiency in 15 patients with double primary cancer of the colorectum and
stomach, immunohistochemically.  The results were compared between the double primary
cancer group of 15 patients and the control group consisting of 155 colorectal cancer (CRC)
patients who had never developed other malignant diseases.  Patients with hereditary
nonpolyposis colorectal cancer and familial adenomatous polyiposis were excluded from
both groups.  The MMR deficiency in CRC was significantly more frequently detected in
the double primary cancer group than in the control group (46.7% versus 20.6%, P <
0.05).  Patients with MMR-deficient CRC of the double primary cancer group were
significantly older, more frequently had poorly differentiated lesions, had less metastases
to the liver and lymph node, and were more advanced in depth of invasion than those of
the control group.  We concluded that MMR deficiency might correlate with the
development of double primary cancer of the colorectum and stomach.  Patients with
MMR-deficient CRC need periodical and intensive follow-up against the development of
double primary cancer.
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Hereditary nonpolyposis colorectal cancer
(HNPCC) is one of the most common predisposi-
tion syndromes for cancer caused by germ-line
mutations in DNA mismatch repair (MMR) genes
(Leach et al., 1993; Bronner et al., 1994; Nicolaides
et al., 1994).  This syndrome is characterized by
development at an early age, frequent occurrence
on the right side, histology of poorly differentiated
and mucinous adenocarcinomas and a favorable
prognosis (Vasen et al., 1991; Kunitomo et al.,
1992; Lynch et al., 1993, 1996).  Another feature of
HNPCC is the development of multiple primary
colorectal cancer (CRC) (Horii et al., 1994; Brown
et al., 1998; Masubuchi et al., 1999; Pedroni et al.,
1999).  Nearly 5% to 10% of CRC patients develop
a 2nd primary CRC within 10 years after surgical
removal of the 1st tumor (Tsukuma et al., 1994),
and genetic instability might play an important role
in developing multiple primary CRC:  synchronous
tumors tend to have more frequent microsatellite
instability (MSI) than metachronous ones (Horii et
al., 1994).  HNPCC is also characterized by fre-
quently occurring extracolonic tumors, especially
of the stomach, small intestine, upper urologic tract
(renal pelvis and ureter) and endometrium (Vasen
et al., 1991; Lynch et al., 1996).  Women with endo-
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metrial cancer and CRC who had their 1st tumor
diagnosed before age 50 demonstrated a high fre-
quency of MSI (Planck et al., 2002).
Gastric cancer is the most prevalent extra-
colonic malignancy in double primary cancer with
colon cancer (Duval et al., 2002).  Several studies
have reported relations between MSI and gastric
cancer:  PCR analysis of primary gastric cancer de-
tected one or more MSIs associated with an increas-
ed occurrence of remnant gastric cancer (Nakachi et
al., 1999).  According to Kim et al. (2002), Helico-
bacter pylori infection might lead to a deficiency of
DNA MMR in gastric epithelial cells, which might
increase the risk of mutation accumulation in gas-
tric mucosa cells and the risk of gastric cancer.  But
reports were few on the contribution of MSI in
double primary cancer of the colorectum and stom-
ach.
In the present study, we have immunohisto-
chemically detected an MMR deficiency in double
primary cancer of the colorectum and stomach, and
analyzed clinical implications of the deficiency in
the cancer.
Materials and Methods
Patients and specimens
Specimens were 15 lesions each of CRC and gastric
cancer removed from 15 patients with double pri-
mary cancer in surgery with curative intent between
January 1990 and December 1996 at the First
Department of Surgery, Tottori University Hos-
pital.  Lesions of HNPCC and familial adenomatous
polyposis were excluded.   All patients were fol-
lowed-up until December 2001.  CRC was clinico-
pathological determined according to the criteria of
the Japanese Society for Cancer of the Colon and
Rectum (1998); and gastric cancer, with the rules of
the Japanese Research Society for Gastric Cancer
(1999).  Double primary cancers of the colorectum
and stomach were synchronous in 5 patients and
metachronous in 10 patients.
From patients who had undergone surgically
curative resection in our hospital during the same
period, a total of 155 CRC patients exclusive of
those with HNPCC and familial adenomatous poly-
posis, served as controls.  The patients developed
no other malignant diseases before the surgery or
during the follow-up period.
After the resection, all specimens were fixed
in 10% neutralized formalin and embedded in par-
affin.  A representative block of each tumor was se-
lected and used to evaluate the expression of
hMLH-1 and hMSH-2.
Immunohistochemistry
The paraffin-embedded sections were dewaxed, re-
hydrated through a graded alcohol series and wash-
ed with distilled water.  Antigen retrieval was per-
formed by microwave oven (700 W) for 12 min.
Endogenous peroxidase was blocked by methanol
containing 2% hydrogen peroxide.  Tissues were
further blocked by incubation for 30 min with 1%
bovine serum albumin in phosphate-buffered sa-
line.  Sections were incubated overnight at 4˚C with
one of the primary antibodies, hMLH-1 (PharMingen,
San Diego, CA) at a dilution of 1/100 and hMSH-2
(Oncogene Sciences, Cambridge, MA) at a dilution
of 1/200.  Antibody binding was detected using a
Vectastain Elite ABC kit (Vector Laboratories Ltd,
Burlingame, CA), based on the biotin-avidin sys-
tem (manufacturer’s protocol).  Sections were
stained with a solution of diaminobenzidine and
hydrogen peroxide solution, and then counter-
stained with methyl green.  Normal colorectal tissue
adjacent to the cancer was used as a positive con-
trol.  Loss of expression in the tumor was recorded
when staining was negative in malignant cells, but
positive in adjacent normal epithelial cells (Figs. 1
and 2).
Statistical Analysis
The differences of MMR deficiency between
groups and the associations between clinicopathol-
ogical factors and hMLH-1 and/or hMSH-2 expres-
sion were evaluated by chi-square test.  Survival
curves were constructed by Kaplan-Meier’s method
and the differences were examined by log rank test.
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Fig. 1.  Immunohistochemical staining of hMLH1 in colorectal cancer (CRC).  hMLH1 protein reveals abundant
nuclear stainings in CRC cells which are not deficient in mismatch repair (MMR) (a).  MMR-deficient CRC cells (b)
show negative staining of hMLH1 protein (original magnification, × 200).
P values less than 0.05 were considered statistically
significant.
Results
Clinicopathological features of 15 patients with
double primary cancer of the colorectum and sto-
mach are shown in Table 1.  The double primary
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Fig. 2.  Immunohistochemical staining of hMLH1 in gastric cancer.  hMLH1 protein reveals abundant
nuclear stainings in gastric cancer cells which are not deficient in mismatch repair (MMR) (a).  MMR-
deficient gastric cancer cells (b) show negative staining of hMLH1 protein (original magnification, × 200).
a
b
cancer group consisted of 5 patients with synchro-
nous double primary cancer (median age 75.4
years, ranges 68–88 years) and 10 patients with
metachronous double primary cancer.  Among the
10 patients, 2 patients developed their 1st cancer in
the colorectum at the age of 63 and 69 years, respec-
tively, with the intervals between the 1st and 2nd
onsets were 6 and 8 years, respectively.  The re-
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Table1. Clinicophathological features of 15 patients with double primary cancer of the colorectum
and stomach
Patient   Sex        Colorectal cancer         Gastric cancer
  num-    Expression       Age at       Expression       Age at       Depth       Lymph       Histological       Stage
   ber           of           diagnosis            of            diagnosis        of            node              differ-
MLH1  MSH2 (year)     MLH1  MSH2     (year)      invasion   metastasis      entiation
  1 M – + 72 – + 49 t3 1 por IIIA
  2 M – + 70 – + 49 t1 0 por IA
  3 M + + 61 + + 50 t2 1 pap II
  4 M + + 72 + + 68 t1 0 tub IA
  5† M – + 68 + + 68 t1 0 pap IA
  6† M – + 88 + + 88 t1 0 tub IA
  7† M + + 72 + + 72 t1 0 tub IA
  8 F – + 71 + + 65 t3 1 pap IIIA
  9* M + + 63 + + 71 t1 0 tub IA
10† F + + 76 + + 76 t3 3 muc IV
11 M – + 63 + + 61 t1 0 tub IA
12* M + + 69 + + 75 t2 1 por IIIA
13 M + + 73 + + 61 t3 2 por IIIB
14† M + – 73 + + 73 t1 0 tub IA
15 F + + 58 + + 47 t2 0 por IB
t1, invasion within submucosa; t2, invasion from the muscularis propria to submucosa; t3, penetration to serosa; t4,
invasion to adjacent organs.
F, female; M, male; muc, mucinous adenocarcinoma; pap, papillary adenocarcinoma; por, poorly differentiated
adenocarcinoma; tub, tubular adenocarcinoma.
* Patients who  developed colorectal cancer previous to gastric cancer.
† Patients who  developed colorectal and gastric cancer synchronously.
maining 8 patients developed their 1st cancer in the
stomach at the median age of 56.3 years (ranges 47–
65 years), with the median interval between onsets
of 11.3 years (ranges 2–23 years).
Table 2 compares the clinicopathological find-
ings of CRCs between the double primary cancer
and control groups.  The incidence of MMR-defici-
ent CRC was significantly higher (P < 0.05) in the
double primary cancer group (7/15, 46.5%) than in
the control group (32/155, 20.6%).  In the double
primary cancer group, MMR tended to be deficient
in patients who were older, had less liver-and-
lymph-node metastases and were advanced in depth
of invasion than in patients of the control group.
In both groups, patients with MMR-deficient
CRC tended to show localization proximal to the
colon (60.0% versus 40.0% and 28.2% versus 17.5%,
respectively) and poorly differentiated and muci-
nous adenocarcinomas in histology (100% versus
38.5% and 45.1% versus 17.0%, respectively); both
features are characteristics of HNPCC.  Further-
more, MMR-deficient CRCs tended to be less in
venous invasion (22.2% versus 66.7% and 5.7%
versus 51.0%, respectively) and liver metastasis
(0.0% versus 50.0% and 11.1% versus 21.2%, res-
pectively) than non-MMR-deficient CRCs (Table
2).
MMR-deficient gastric cancer was immuno-
histochemically detected in 2 (13.3%) of the 15 pa-
tients of the double primary cancer group.  The 2
patients had the same deficient MMR gene protein
(MLH1) in both CRC and gastric cancer.  Further-
more, the 2 patients had several common clinico-
pathological features:  both were male, their cancers
were poorly differentiated in histology and the pre-
ceding gastric cancer developed at a younger age.
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Table 2.  Clinicophathological features and MMR deficiency in the double primary cancer group and
control group
   Double cancer group       Control group P value
      MMR deficiency     MMR deficiency
            Positive            Positive
 Number/Total % Number/Total %
Patients 7/15 46.7 32/155 20.6 0.022
Age (year) 60 ≥ 7/14 50.0 27/118 22.9 0.028
60 < 0/1 0.0   5/37 13.5 0.693
Sex Male 6/12 50.0 18/75 24.0 0.061
Female 1/3 33.3 14/80 17.5 0.484
Location of tumor Proximal 3/5 60.0 11/39 28.2 0.151
Distal 4/10 40.0 21/116 18.1 0.061
Histological type Poorly diff. and mucinous 2/2 100   9/20 45.0 0.136
    adenocarcinomas
Others 5/13 38.5 23/135 17.0 0.060
Depth of invasion t1 0/2 0.0   1/13 7.7 0.685
t2, t3, t4 7/13 53.8 31/142 21.8 0.010
Liver metastasis Positive 0/1 0.0   1/9 11.1 0.725
Negative 7/14 50.0 31/146 21.2 0.016
Lymph node metastasis Positive 2/7 28.6   9/45 20.0 0.606
Negative 5/8 62.5 23/110 20.9 0.008
Venous invasion Positive 2/9 22.2   6/104 5.7 0.065
Negative 4/6 66.7 26/51 51.0 0.467
Lymphatic invasion Positive 3/5 60.0 14/63 22.2 0.060
Negative 4/10 40.0 18/92 19.6 0.136
t1, invasion within submucosa; t2, invasion from the submucosa to the muscularis propria; t3, penetration to serosa;
t4, invasion to adjacent organs.
diff., differentiated; MMR, mismatch repair.
Discussion
Multiple CRC occurs in 5 to 10% of CRC patients
(Enker et al., 1978; Rennert et al., 1995), and over
85% of multiple CRC patients show MSI (Horii et
al., 1994; Masubuchi et al., 1999).  In our study, the
incidence of double primary cancer was 8.8% (15/
170) in CRC patients, and the incidence of an MMR
deficiency in CRC of double primary cancer pa-
tients was 46.7% (7/15), consistently with a report-
ed level (Kim et al., 2001).  The incidence of multi-
ple CRC and that of double primary cancer were
similar in CRC patients; however, the incidence of
an MMR deficiency was lower in double primary
cancer patients than in multiple CRC patients.
These findings indicate that MMR deficiency plays
a more important role in carcinogenesis in the colo-
rectum than in other extracolonic sites.
MMR-deficient CRC shows localization in the
proximal colon and poor histological differenti-
ation, which are characteristics of HNPCC.  As re-
ported, genetic instability might play an important
role in developing multiple primary CRC (Horii et
al., 1994); however, our data suggested that patients
with MMR-deficient CRC may also have a risk of
developing double primary cancer.  Furthermore,
MMR-deficient CRCs were more advanced in
depth of invasion but less frequent in venous inva-
sion and liver metastasis than non-MMR-deficient
CRCs.  This tendency was more marked in the dou-
ble primary cancer group than in the control group.
Tumors with an MMR deficiency might affect some
factors and suppress spreading cancer cells.
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MMR-deficient tumors reduce the expression
of COX-2 protein (Karnes et al., 1998) and suppress
the expression of vascular endothelialgrowth factor.
This factor is very potent in tumor angiogenesis and
plays an important role in the migration and growth
of vascular endothelial cells, the promotion of vas-
cular permeability and the formation of vascular ca-
nals (Connolly et al., 1989; Leung et al., 1989).
These reports could explain the few vessel inva-
sions in tumors with an MMR deficiency.  Also, in
another of our studies (in submission), we reported
that MMR-deficient tumors tended to express β2-
microglobulin protein at a lower level than non-
MMR-deficient tumors, and that MMR-deficient
tumors might evoke an immune response.  This also
may be a reason for the favorable prognosis of pa-
tients with MMR-deficient CRC.
Of the 15 gastric cancer patients of the double
primary cancer group, 2 patients (13.3%) had an
MMR deficiency, and their deficient MMR gene
protein (MLH1) was the same in CRC and gastric
cancer, similarly as reported (Kim et al., 2001).  An
MMR deficiency could relate to carcinogenesis of
double primary cancer in the colorectum and stom-
ach, but the incidence of an MMR deficiency in
gastric cancer was lower than that in CRC.  Thus, an
MMR deficiency seems to affect the development
of gastric cancer to some extent, which is not so
marked as in development of CRC.
In the present study, we observed that an
MMR deficiency of CRC was more frequent in the
double primary cancer group than in the controls.
Patients with MMR-deficient CRC or gastric cancer
need periodical and intensive follow-up focusing
not only on metachronous multiple CRC but also on
double primary cancer.
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